Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25310534 | 1.00 | LMNA (0.52) | LMNAHRH4HRH3PTPN1CDC25B | |
| SCHEMBL25307508 | 0.85 | LMNA (0.55) | LMNAHRH4HRH3PTPN1CDC25B | |
| SCHEMBL25307505 | 0.85 | LMNA (0.55) | LMNAHRH4HRH3PTPN1CDC25B | |
| SCHEMBL10946861 | 0.81 | TSHR (0.35) | TSHR | |
| SCHEMBL10420228 | 0.79 | LMNA (0.54) | LMNAHRH4HRH3TSHRTAAR1 | |
| SCHEMBL19559233 | 0.79 | LMNA (0.54) | LMNAHRH4HRH3TSHRTAAR1 | |
| SCHEMBL17749356 | 0.79 | LMNA (0.56) | LMNAHRH4HRH3PTPN1CDC25B | |
| SCHEMBL4794721 | 0.79 | LMNA (0.58) | LMNAHRH4HRH3PTPN1CDC25B | |
| SCHEMBL1335990 | 0.79 | LMNA (0.58) | LMNAHRH4HRH3PTPN1CDC25B | |
| SCHEMBL5237882 | 0.79 | LMNA (0.58) | LMNAHRH4HRH3PTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12516046-B2 | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2025-02-27 | — | — | US | disclosed |
| CN-118251389-A | Pyridyl derivatives as sodium channel activators | 泽农医药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | ABBVIE INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | ABBVIE INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023141536-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO [3',2':5,6] PYRIDO[2,3-B] [1,4] OXAZEPINE BC1-2 INHIBITORS | ABBVIE INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-2751104-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-07-09 | — | — | EP | disclosed |
| US-8754071-B2 | Compounds and compositions as c-kit kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-06-17 | — | — | US | disclosed |
| US-20140031333-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2014-01-30 | — | — | US | disclosed |
| US-8569283-B2 | Compounds and compositions as c-Kit kinase inhibitors | IRM LLC (BM) | 2013-10-29 | — | — | US | disclosed |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | US | disclosed |
| WO-2013033167-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | IRM LLC (BM) | 2013-03-07 | — | — | WO | disclosed |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2391212-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010088167-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | LMNA 1548/4885HRH4 1066/4885HRH3 846/4885 |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | LMNA 574/4885HRH4 3492/4885HRH3 1849/4885 |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L1, BCL2L2 | LMNA 975/4885HRH4 1435/4885HRH3 1535/4885 |
| US-20140031333-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | LMNA 900/4885HRH4 3623/4885HRH3 2306/4885 |
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | LMNA 287/4885HRH4 1149/4885HRH3 844/4885 |
| US-20130059832-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | LMNA 900/4885HRH4 3623/4885HRH3 2306/4885 |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | BCL9L, BCL2L1, BCL2L2 | LMNA 975/4885HRH4 1435/4885HRH3 1535/4885 |
| US-11802122-B2 | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors | SCN8A, TRPV1, SCN2A | LMNA 3683/4885HRH4 170/4885HRH3 438/4885 |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | BCL9L, BCL2L1, BCL9 | LMNA 964/4885HRH4 1479/4885HRH3 1580/4885 |
| US-20230312528-A1 | 2-OXO-IMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | SCN8A, TRPV1, SCN2A | LMNA 3647/4885HRH4 183/4885HRH3 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.